News

A statistically significant improvement in overall survival (OS) was not seen with the combination of paclitaxel and the angiogenesis inhibitor trebananib when compared with paclitaxel alone for patients with recurrent platinum-resistant ovarian cancer.

Capitalizing on cellular apoptotic pathways to eradicate cancer cells holds much interest because it harnesses the body’s natural defense systems, and because dysregulation of apoptosis occurs frequently in cancer.

Characterized by the absence of cell surface receptors for estrogen, progesterone and epidermal growth factor, triple negative breast cancer (TNBC) presents a formidable treatment challenge.

Early diagnosis of lung cancer is crucial, because surgery is curative only in the early stages. However, by the time most patients experience symptoms, the cancer has already progressed beyond the point of successful surgery.

The FDA has granted a breakthrough therapy designation to pembrolizumab for the treatment of patients with NSCLC who are EGFR mutation- or ALK rearrangement-negative and whose disease has progressed on or following platinum-based chemotherapy.

The development of drug resistance in cancer cells presents a major obstacle to cancer treatments of all types, including small molecule inhibitors, monoclonal antibodies, and hormone therapy.

New research has identified a genetic variant that helps reduce the risk of breast cancer in some Latina patients by 40% to 80%.

TAS-102 (tipiracil hydrochloride) has received a fast track designation from the FDA as a treatment for patients with refractory metastatic colorectal cancer (mCRC), according to an announcement by Taiho Oncology, the company developing the drug in the US.

A “nano-cocoon” DNA drug delivery vehicle may offer several advantages over other nanotechnology-based delivery systems, according to new research.

The investigational chimeric antigen receptor (CAR) therapy CTL019 elicited complete remissions in 27 of 30 pediatric and adult patients (90%) with relapsed/refractory acute lymphoblastic leukemia (ALL) in 2 pilot trials.

The FDA has granted a priority review to the oral multiple tyrosine kinase receptor inhibitor lenvatinib as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).

Two agents with contrasting mechanisms of actions exert synergistic effects while limiting tumor blood supply in ovarian cancer. Patient enrollment began this month (October 2014) for a new phase 1b/2 clinical study1 to evaluate this novel combination with the VDA fosbretabulin plus pazopanib.

Production of the prostate cancer drug radium-223 (Xofigo) has been suspended indefinitely by its maker, Bayer HealthCare Pharmaceuticals, due to a manufacturing problem. The company confirmed the manufacturing suspension in a statement released to Targeted Oncology.

The FDA has expanded the approval of Lymphoseek (technetium Tc 99m tilmanocept) injection to include sentinel lymph node (SLN) detection for breast cancer and melanoma as well as lymphatic mapping in solid tumors.

The FDA has assigned a priority review designation to palbociclib in combination with letrozole as a frontline treatment for postmenopausal patients with ER-positive, HER2-negative advanced breast cancer.

The FDA has approved bortezomib (Velcade) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) as a frontline treatment for patients with mantle cell lymphoma.

The FDA has approved NEPA (Akynzeo) to treat nausea and vomiting in patients undergoing chemotherapy as part of their cancer treatment.

The FDA has assigned a priority review designation to blinatumomab as a treatment for adult patients with Philadelphia chromosome-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia.

The FDA has scheduled an ODAC advisory hearing to discuss the NDA for panobinostat in combination with bortezomib and dexamethasone for patients with multiple myeloma who have received at least one prior therapy.

To gain further insight into AR-V7 and resistance to AR-targeting agents, Targeted Oncology interviewed the lead author, Emmanuel S. Antonarakis, MBBCh, an assistant professor at Johns Hopkins Medicine.

Several clinical trials combining nivolumab (Opdivo) with targeted therapies against ALK, c-MET, and T790M for patients with non-small cell lung cancer (NSCLC) have been established as part of a collaboration between Novartis and Bristol-Myers Squibb (BMS).

The highly selective ALK inhibitor AP26113 has been granted a Breakthrough Therapy Designation by the FDA for the treatment of patients with ALK-positive metastatic NSCLC who received prior treatment with crizotinib.

The FDA has assigned a priority review designation to nivolumab for pretreated patients with advanced melanoma, setting an action date for the drug as March 30, 2015.

The 12 month countdown to the adoption of ICD-10 has begun.

To gain further insight into the expanded approval of this agent, Targeted Oncology interviewed Tomasz M. Beer, MD, a co-principal investigator on the PREVAIL trial.

Last week, the FDA approved pembrolizumab (Keytruda) for the treatment of patients with advanced or unresectable melanoma following progression on prior therapies.

The combination of ramucirumab and FOLFIRI significantly improved overall survival and progression-free survival compared with chemotherapy alone as a second-line treatment for patients with mCRC.

Bristol-Myers Squibb has filed a lawsuit over Merck’s newly approved immunotherapy drug pembrolizumab, contending that the much-heralded PD-1 inhibitor will infringe upon patents that Bristol-Myers holds on the groundbreaking technology.

The FDA has expanded the approval for enzalutamide (Xtandi) to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).

This activity is supported by an educational grant from Eli Lilly.